peppersite
Peptidesubcutaneous

TB-500 / TB4

TB-500 is a lab-made fragment of thymosin beta-4, a larger peptide found throughout the body, with the sequence Ac-LKKTETQ. It is studied in cell-repair and blood-vessel-growth research, though most of the supporting work used the full-length protein rather than this fragment.

Researched for
Tissue RepairSoft Tissue RecoveryTendon/Ligament RecoveryInjury RecoveryPerformance RecoveryRecovery

At a glance

Type
Peptide
Given by
subcutaneous
Evidence
Not yet audited here; the reference library calls it emerging
Reported amount
2 mg per Peptide Dosing Protocols. All 4 sources
Typical vial
10 mg in 2 mL

How much to draw

Full calculator →
Your draw
40units
0.4 mL on a U-100 insulin syringe
5 mg/mL5 doses per vial
Amount per dose

Opened on 2 mg, the figure Peptide Dosing Protocols reports for TB-500 / TB4, and a 10 mg vial in 2 mL. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for TB-500 / TB4 or for anything else, and nothing below has been checked against the study it came from.

Standard: 2-2.5 mg subcutaneous twice weekly · Low: 2 mg twice weekly · High: 2.5 mg subcutaneous once weekly
Frequency
twice weekly for loading, once weekly for maintenanceWeeks 1-6 for loading, Weeks 7-12 for maintenance · 4-12 weeks
Route
subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysTB-500 is commonly dosed at 2-2.5 mg subcutaneously twice weekly during the loading phase.
2-2.5 mg SC twice weekly (loading 4-6 weeks), then 2 mg weekly maintenance
Frequency
twice weekly (loading), then weekly4-6 week loading, then maintenance · Loading phase then maintenance phase
Route
subcutaneous
Reported by
Commonly published practitioner dosing range - provider confirmation required.
2-2.5 mg per injection (loading); 750 mcg-2 mg (maintenance)
Frequency
not stated
Route
subcutaneous or oral or topical
Reported by
Peptide Protocol Wiki
Referenced with a loading phase of 5-10 mg weekly for 4-6 weeks, then maintenance at 2-5 mg weekly split into smaller doses. Results typically noticed within 2-4 weeks. Caution flag: angiogenesis-promoting, so cancer or tumor history warrants medical consultation first.
Frequency
Weekly total (2-10 mg) split into smaller doses · Post-workout or before bedOn-cycle 4-6 weeks, off-cycle 1-2 months
Route
subcutaneous or intramuscular
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • 2.0 mL bacteriostatic water for 10 mg vial
  • Commonly 5 mg or 10 mg vials · Reconstitute with bacteriostatic water
  • Bacteriostatic water
Not yet audited

We have not published an audit on TB-500 / TB4. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

TB-500 keeps the part of thymosin beta-4 that binds actin, a protein involved in how cells move and rebuild tissue, and the parent peptide also promotes angiogenesis, the growth of new blood vessels, and influences inflammatory signaling. The fragment holds onto that actin-binding behaviour in cell experiments and animal studies, but it leaves out the rest of the parent peptide's structure. Most of the research cited for it, including heart-attack work in mice and pigs, tendon and ligament work in rats, and human trials in wounds and eye disease, used the full 43-amino-acid protein. There is no published human randomized trial of the injectable 7-amino-acid fragment for any purpose, so the common claim that it heals tendons and ligaments in people rests on extrapolation.

In technical termsActin regulation; potential cell migration and repair signaling.

What we don't know

Whether the fragment works in people: no published human randomized trial has tested injectable TB-500 for any purpose. The claim that it heals tendons and ligaments in people rests on carrying over animal work done with the full-length protein.

Fragment versus full protein: a scoping review covered in our audit included 80 studies, and one of them tested TB-500 directly. Whether the fragment behaves like full-length thymosin beta-4 is not settled by that literature.

Tendon, ligament and muscle: the same review found these areas comparatively sparse. Human evidence was concentrated in eye and skin wound settings.

Long-term safety: whether injections of the fragment carry a meaningful cancer risk in healthy adults has not been studied. Long-term immune effects across repeated cycles are uncharacterized in humans.

Reported side effects

Seen in studies: the closest human reference is a Phase 1 study of the full-length protein, in which 40 healthy volunteers received intravenous amounts up to 1260 mg daily for 14 days with no serious adverse events and no dose-limiting toxicities. That does not automatically carry over to injecting the fragment under the skin for weeks or months.

Reported by users: mild discomfort and redness where the injection was given, plus short-lived fatigue or a feeling of head pressure in the first few days of a cycle.

Not ruled out: thymosin beta-4 levels are raised in some cancers that have spread, and the peptide promotes new blood vessel growth, so whether small injections of the fragment carry meaningful risk in healthy adults has not been studied. The peptide also regulates inflammatory signaling, and long-term immune effects across repeated cycles are uncharacterized in humans. Research-use peptides are made outside FDA-approved pipelines, so purity, sterility and identity vary between suppliers, and standard injection risks include local irritation, lumps from poor site rotation and infection from poor technique.

Who should avoid it

Athletes subject to drug testing: TB-500 and all thymosin beta-4 derivatives are banned by WADA at all times under Section S0, non-approved substances, with detection windows reported at 30 to 45 days, which covers athletes in WADA-tested sports, NCAA athletes and military personnel under WADA-aligned testing.

People with active or prior cancer: thymosin beta-4 is linked to increased spread in some tumour models, described as a theoretical concern rather than a settled clinical risk.

People who are pregnant or breastfeeding: no human data establish safety in these contexts.

People allergic to peptide preparations or to benzyl alcohol, the preservative in bacteriostatic water: it can cause allergic reactions in a small number of users, and repeated injections raise the exposure.

People with an infection at the planned injection site: standard injection cautions apply to broken, infected, inflamed or recently bruised skin.

People seeking treatment for a medical condition: TB-500 is not a treatment, and care for a wound, tendon injury or heart condition belongs with a clinician through approved pathways.

What gets monitored

Monitor injection site condition, sleep quality, cycle adherence, and any new or unusual symptoms. Baseline and end-of-cycle resting heart rate and blood pressure are suggested. (reported by Peptide Dosing Protocols)

Regulatory status

FDA approval: TB-500 is not approved by the FDA for any human use.

Compounding: on July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding TB-500 to the list of substances pharmacies may compound. The vote is advisory and does not bind the FDA. Adding a substance to the list needs formal FDA rulemaking, and news reports from July 23 and 24, 2026 said the FDA had made no final decision. FDA staff scientists had objected, citing a lack of safety and effectiveness data. None of this is FDA approval of TB-500 as a drug.

Sport: the reference entry says TB-500 and all thymosin beta-4 derivatives are prohibited at all times by the World Anti-Doping Agency under section S0, its class for non-approved substances.

Checked: November 2026.

Common questions

What is TB-500?

It is a lab-made 7-amino-acid fragment of thymosin beta-4, a larger peptide found throughout the body. One end is acetylated, a change that can slow its breakdown.

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a 7-amino-acid fragment matching positions 17 to 23 of the 43-amino-acid full-length thymosin beta-4. Most of the published human and animal research used the full-length protein.

What is TB-500 researched for?

It is most often referenced in research-use contexts around actin-mediated cell movement and tissue-repair signaling. No published human randomized trial of the injectable fragment exists for any purpose.

What amounts are reported for TB-500?

Reported amounts and schedules for TB-500 / TB4 differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

How is TB-500 reconstituted?

That depends on the vial size and how much water is added. The calculator on this page works out the draw for any combination, and the reconstitution guide covers the steps.

How long is a typical TB-500 cycle?

Research-use cycles are commonly described as running 4 to 12 weeks, usually with a 4 to 6 week loading phase followed by maintenance. These are community conventions, not trial-derived schedules.

Are BPC-157 and TB-500 used together?

The BPC-157 and TB-500 pairing is commonly reported in the research-use community. No trial has tested the combination.

Is TB-500 FDA-approved?

No. TB-500 is not approved by the FDA for any human use. It is also banned by WADA at all times.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things